Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee.

Abstract

GUIDELINE QUESTIONS: 1) Does erythropoietin (EPO) reduce the need for transfusion of red blood cells in patients receiving chemotherapy for a nonhematologic cancer? 2) Does the administration of EPO improve the quality of life of these cancer patients? OBJECTIVE: To make recommendations regarding the use of EPO to reduce the need for transfusion of red blood cells in patients receiving chemotherapy for a nonhematologic cancer.

Authors

Quirt I; Micucci S; Moran LA; Pater J; Browman G

Journal

Cancer prevention & control : CPC = Prévention & contrôle en cancérologie : PCC, Vol. 1, No. 3, pp. 241–248

Publication Date

August 1997

ISSN

1206-548X

Associated Experts

James Rusthoven

Professor Emeritus, Faculty of Health Sciences

Visit profile

Labels

Fields of Research (FoR)

4203 Health Services and Systems 32 Biomedical and Clinical Sciences 42 Health Sciences

Medical Subject Headings (MeSH)

Anemia Antineoplastic Agents Drug Costs Erythrocyte Transfusion Erythropoietin Follow-Up Studies Humans Hypertension Meta-Analysis as Topic Neoplasms Outcome Assessment, Health Care Platinum Compounds Quality of Life Randomized Controlled Trials as Topic Risk Factors